FDA Logo links to FDA home page
Center for Biologics Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Biologics Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

horizonal rule
CBER links to product areas
CBER links
horizonal rule

Recall of Amplicor HIV-1 Monitor Test, v 1.5

horizonal rule

DATE RECALL INITIATED:

June 24, 2004

PRODUCT / LOT NUMBER / EXPIRATION DATE:

Amplicor [3] AV-HRP Avidin-HRP (Horseradish Peroxidase) BGG Conjugate, Lot No. E09569, found in kit Lot No. E11360, Material No. 21118560018, expiration January, 2005

Amplicor [3] AV-HRP Avidin-HRP (Horseradish Peroxidase)BGG Conjugate, Lot No. E09569, found in kit Lot No. E11231, Material No. 21117750123, expiration September, 2004
    NOTE: This product was only distributed to foreign consignees.

MANUFACTURER:

Roche Molecular Systems, Inc
Belleville, New Jersey

REASON:

Roche has confirmed increased frequency of occurrence of “blue foci” with the Avidin-Horseradish Peroxidase (AV-HRP) Conjugate Lot E09659. This lot is included as a component in the kits listed above. “Blue foci” are blue particulates in the microwell plate that are visible in manual methods following the addition of conjugate and substrate to the wells during the detection process. Increased frequency of the occurrence of “blue foci” may lead to elevated and/or observed out of sequence optical density readings in the microwell plate assays that have used this particular lot of reagent. The investigation determined that AV-HRP Conjugate, Lot E09659, exhibited a higher frequency of “blue foci” when compared to previous lots of conjugate, and that the frequency of blue foci in this particular lot may be increasing with the age of the reagent. Consignees have been asked to contact the manufacturer to arrange for product return.

horizonal rule

The information in this listing reflects CBER's best efforts to communicate information that has been reported to FDA. Its accuracy and comprehensiveness cannot be guaranteed.

 

 
horizonal rule